Jefferies Maintains Buy on PTC Therapeutics, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Kelly Shi maintains a Buy rating on PTC Therapeutics (NASDAQ:PTCT) and raises the price target from $35 to $46.
May 20, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Kelly Shi maintains a Buy rating on PTC Therapeutics and raises the price target from $35 to $46.
The raised price target from $35 to $46 by Jefferies, along with the maintained Buy rating, is likely to positively impact PTCT's stock price in the short term as it reflects increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100